

CS/NSE/UFR/2012-13
February 12, 2013

TO
THE MANAGER
LISTING DEPARTMENT
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
EXCHANGE PLAZA, BANDRA KURLA COMPLEX
BANDRA (E), MUMBAI – 400 051

Dear Sir/Madam,

Stock Code – SUVEN-EQ

Sub: Notification of Un-audited Financial Results for the quarter ended 31/12/2012 – Clause 41

.....

With reference to the above subject, we are forwarding here with Un-audited Financial Results of our Company for three/nine months ended 31st December, 2012 in the prescribed proforma, as required under Clause-41 of the listing agreement as amended. The Board of Directors of our company has taken on record the enclosed Un-audited Financial Results for the 3rd quarter in its meeting held on 12th February, 2013 and Limited Review Report of Auditors of the Company

Please find enclosed press release of our company. We request you to take these documents on your records

Thanking You,

Yours faithfully,
For SUVEN LIFE SCIENCES LIMITED


K HANUMANTHA RAO
Company Secretary

Suven Life Sciences Limited

Regd. Office: Serene Chambers, Road # 5, Avenue 7, Banjara Hills, Hyderabad 500 034, INDIA
Tel: 91~40~2354 1142/ 3311/ 3315 Fax: 91~40~2354 1152
info@suven.com www.suven.com



SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034
UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st DEC 2012

(Rs in lakhs), except share data

PART - I

Sl. No.	PARTICULARS	Quarter Ended			Year to date figures		Previous Year Ended
		31/12/2012	30/09/2012	31/12/2011	31/12/2012	31/12/2011	31/03/2012
		Unaudited	Un-audited	Unaudited	Unaudited	Unaudited	Audited
1	Income from operations						
	(a) Net sales/income from operations (Net of excise duty)	6,239.48	5,025.90	4,863.70	18,318.10	14,131.36	20,420.78
	(b) Other operating income	-	-	-	-	-	-
	Total income from operations (net)	6,239.48	5,025.90	4,863.70	18,318.10	14,131.36	20,420.78
2	Expenses						
	a) Cost of materials consumed	2,364.64	1,683.66	2,125.68	6,192.93	5,658.34	8,145.56
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(773.81)	(301.91)	(879.48)	(744.88)	(982.83)	(564.74)
	d) Employee benefits expense	768.53	562.82	583.66	1,983.08	1,649.34	2,283.03
	e) Depreciation and amortisation expense	219.01	170.05	138.27	572.29	417.01	599.79
	f) Other expenses - Manufacturing Exps	1,014.79	893.71	736.75	2,757.05	1,876.52	2,667.83
	- Selling Exps	95.36	83.58	41.64	279.15	173.05	216.91
	- Administrative Exps	264.22	596.52	679.22	1,378.16	1,258.18	1,704.57
	- R & D Exps	929.72	682.80	858.01	2,487.20	2,483.14	3,304.91
	- Provision for MTM on Forward contracts	89.38	(314.27)	660.83	26.07	1,202.69	348.06
	Total expenses	4,971.84	4,056.96	4,944.58	14,931.05	13,735.44	18,705.92
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	1,267.64	968.94	(80.88)	3,387.05	395.92	1,714.86
4	Other Income	36.84	(39.26)	156.28	50.05	338.84	190.25
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)	1,304.48	929.68	75.40	3,437.10	734.76	1,905.11
6	Finance costs	468.53	289.75	213.52	1,080.20	570.07	990.93
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)	835.95	639.93	(138.12)	2,356.90	164.69	914.18
8	Exceptional Items	-	-	-	-	-	-
9	Profit/Loss from Ordinary Activities before tax (7 ± 8)	835.95	639.93	(138.12)	2,356.90	164.69	914.18
10	Tax Expenses	60.27	(8.96)	(267.57)	135.99	(556.97)	(522.06)
11	Net Profit/ (Loss) from Ordinary Activities after tax (9 ± 10)	775.68	648.89	129.45	2,220.91	721.66	1,436.24
12	Extraordinary Items (net of tax expense ₹ Lakhs)	-	-	-	-	-	-
13	Net Profit (+)/Loss(-) for the period (11 ± 12)	775.68	648.89	129.45	2,220.91	721.66	1,436.24
14	Share of profit / (loss) of associates*	-	-	-	-	-	-
15	Minority interest *	-	-	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 ± 14 ± 15) *	775.68	648.89	129.45	2,220.91	721.66	1,436.24
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	1,167.32 Re.1.00	1,167.32 Re.1.00	1,167.32 Re.1.00	1,167.32 Re.1.00	1,167.32 Re.1.00	1,167.32 Re.1.00
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year						11,584.83
19.i	Earning Per Share (EPS) (before extraordinary items) (of ₹ 1/- each) (not annualised):						
	a) Basic	0.66	0.56	0.11	1.90	0.62	1.23
	b) Diluted	0.66	0.56	0.11	1.90	0.62	1.23
19.ii	Earning Per Share (EPS) (after extraordinary items) (of ₹1/-each) (not annualised):						
	a) Basic	0.66	0.56	0.11	1.90	0.62	1.23
	b) Diluted	0.66	0.56	0.11	1.90	0.62	1.23



PART - II

	31/12/2012	30/09/2012	31/12/2011	31/12/2012	31/12/2011	31/03/2012
A	Unaudited	Un-audited	Unaudited	Unaudited	Unaudited	Audited
PARTICULARS OF SHAREHOLDING						
1 Public share holdings						
- Number of shares	42,679,160	42,679,160	42,679,160	42,679,160	42,679,160	42,679,160
- Percentage of Share holding	36.56%	36.56%	36.56%	36.56%	36.56%	36.56%
2 Promoters and promoter group Shareholding**						
a) Pledged / Encumbered	NIL	NIL	NIL	NIL	NIL	NIL
- Number of shares						
- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL
- Percentage of shares (as a % of the total share capital of the company)	NIL	NIL	NIL	NIL	NIL	NIL
b) Non-Encumbered	74,052,828	74,052,828	74,052,828	74,052,828	74,052,828	74,052,828
- Number of shares						
- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of shares (as a % of the total share capital of the company)	63.44%	63.44%	63.44%	63.44%	63.44%	63.44%
Particulars	3 months ended (31/12/2012)					
B INVESTOR COMPLAINTS						
Pending at the beginning of the quarter	0					
Received during the quarter	31					
Disposed of during the quarter	31					
Remaining unresolved at the end of the quarter	0					

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED

Rs. In Lakhs

	PARTICULARS	Quarter Ended			Year to date figures		Year Ended
		31/12/2012	30/09/2012	31/12/2011	31/12/2012	31/12/2011	31/03/2012
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	SEGMENT REVENUE :-						
	a) Manufacturing (CRAMS)	5,402.01	4,359.17	4,600.69	16,276.13	13,274.95	19,168.87
	b) Services (DDDSS)	837.46	666.73	271.58	2,041.96	884.03	1,251.91
	c) Research & Development	-	-	-	-	-	-
	Net Sales from Operations	6,239.47	5,025.90	4,872.27	18,318.09	14,158.98	20,420.78
2	SEGMENT RESULTS :-						
	Profit/(Loss) before tax and interest:						
	a) Manufacturing (CRAMS)	1,904.71	1,417.44	1,959.14	5,816.52	4,799.04	6,507.91
	b) Services (DDDSS)	618.02	406.29	111.12	1,255.51	459.45	531.83
	c) Research & Development	(929.72)	(682.80)	(858.01)	(2,487.20)	(2,483.14)	(3,304.91)
	TOTAL	1,593.01	1,140.93	1,212.25	4,584.83	2,775.35	3,734.83
Less:	i) Interest	441.82	261.41	213.52	1,001.37	570.07	888.50
	ii) Other Un-allocable exps net off un-allocable Income	315.24	239.59	1,136.85	1,226.56	2,040.59	1,932.15
	Total Profit Before Tax	835.95	639.93	(138.12)	2,356.90	164.69	914.18
3	CAPITAL EMPLOYED						
	(Segment Assets - Segment Liabilities)						
	a) Manufacturing (CRAMS)	13,053.17	11,544.66	14,356.18	13,053.17	14,356.18	10,704.10
	b) Services (DDDSS)	3,035.70	3,137.56	312.27	3,035.70	312.27	3,298.34
	c) Research & Development	2,157.59	2,513.05	2,973.76	2,157.59	2,973.76	2,228.26
	d) Net assets which are not segmented and used	4,237.93	4,613.35	4,103.06	4,237.93	4,103.06	2,023.90
	TOTAL	22,484.39	21,808.62	21,745.27	22,484.39	21,745.27	18,254.60

- Notes: 1) The above un-audited results were approved and taken on record at the Board of Directors' meeting held on 12th Feb '13
2) Previous years figures have been regrouped / reclassified whenever necessary.
3) The limited review has been completed by the Statutory Auditors.
4) Provision for MTM Losses/gains pertaining to Forward Contracts entered for covering the future receivables in USD.
5) Suven Nishta Pharma Pvt Ltd, the 100% subsidiary, has been merged w.e.f. 1st Jan 2012 and accordingly the results have been prepared. Hence the current year's figures are not comparable with the previous year figures.

Place : Hyderabad
Date : 12th Feb' 2013

For SUVEN LIFE SCIENCES LTD

VENKAT JASTI
Chairman & CEO

We Deliver



Ref No.LR/010/2012-13:

LIMITED AUDIT REVIEW REPORT

To

The National Stock Exchange Limited
Mumbai.

We have reviewed the accompanying statement of unaudited financial results of M/S. SUVEN LIFE SCIENCES LIMITED, having registered office at 8-2-334, 6th Floor, SDE Serene Chambers, Road No 7, Banjara Hills, Hyderabad – 34, for the period ended on 31.12.2012, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India*. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

for KARVY & CO.,
Chartered Accountants
(Registration No.001757S)


(K. AJAY KUMAR)
P A R T N E R
M.No.21989



Place: Hyderabad
Date : 12.02.2013.

SUVEN Life Sciences



News Release

Suven's PAT up by 500 % for the Qtr ended Dec 2012

HYDERABAD, INDIA (12 Feb' 2013) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its un-audited financial results for the quarter ended 31st Dec 2012. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 12th Feb, 2013 at Hyderabad.

Financial Highlights for the 3rd Quarter ended Dec' 2012:

Growth in revenue	Rs 628 mil vs. Rs 502 mil	- Up by 25 %
Growth in PAT	Rs 78 mil vs. Rs 13 mil	- Up by 500 %
Growth in EBIDTA	Rs 152 mil vs. Rs 21 mil	- Up by 613 %

Financial Highlights for the 9 months ended Dec' 2012:

Growth in revenue	Rs 1837 mil vs. Rs 1447 mil	- Up by 27 %
Growth in PAT	Rs 222 mil vs. Rs 72 mil	- Up by 208 %
Growth in EBIDTA	Rs 401 mil vs. Rs 115mil	- Up by 248 %

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 249 mil (13.54 % on revenue) for the period 9 months ended Dec ' 2012.

During the quarter there were major qualitative achievements with the grant of 8 (eight) product patents from Canada, China, Eurasia and Korea to Suven's drug discovery pipeline which consists of 13 molecules out of which twelve (12) molecules currently in pre-clinical stage of development in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;

